Tumor-derived Jurkat T cells preactivated with anti-CD2/CD3/CD28 antibodies and contacted with the micro-arc CaP coating for 14 days showed a 4.5-fold upregulation in hTERT expression compared with activated malignant cells cultured without test samples. The gene discussed is CD2; the disease is neoplasm.